FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969884035> ?p ?o ?g. }

• W2969884035 endingPage "486" @default.
• W2969884035 startingPage "483" @default.
• W2969884035 abstract "Summary. The antiphospholipid-syndrome (APS) is one of the most severe forms of thrombophilia, which may not only lead to recurrent venous but also to arterial thromboembolic events (TE), and to severe pregnancy complications, respectively. APS is defined by clinical symptoms and specific laboratory findings: 1. Lupus anticoagulant (LA), 2. anticardiolipin-antibodies (ACA), and 3. β2-Glycoprotein I-antibodies (β2GPI-Ab). All test results have to be confirmed after at least 12 weeks. The thrombotic risk is highest, if all 3 test groups are positive. It must be pointed out that the presence of UFH, VKA or DOACs may lead to false positive LA-test results; the addition of a specific absorber after blood sampling may provide reliable results in the presence of DOACs. A prospective randomized controlled trial comparing warfarin and rivaroxaban (TRAPS-trial) including only high-risk patients with triple positive APS was terminated early because of an increased rate of TE in patients treated with rivaroxaban [19 %, mostly arterial, compared to 3 % with warfarin (HR 7.4;1.7–32.9)]. Subsequently, a warning letter was issued by the pharmaceutical manufacturers of DOACs, including a warning of DOAC use in APS-patients, particularly in triple-positive high-risk patients. Conclusions: 1. Clinical suspicion of APS requires careful diagnostic testing. Because of inadequate diagnostic workup, many patients may not even have an APS, and these patients could be adequately treated with a DOAC. 2. Patients with single or double positive antiphospholipid antibodies but without positive LA may have a comparably low thrombotic risk and may also be treated with a DOAC in venous TE – sufficient evidence for that conclusion is not yet available but is suggested by the results of meta-analyses. 3. Triple positive patients or those with APS who suffered from arterial thromboembolism have a very high recurrence risk of thrombosis; the TRAPS-Study shows that these patients should be treated with VKA instead of a DOAC." @default.
• W2969884035 created "2019-08-29" @default.
• W2969884035 creator A5000085570 @default.
• W2969884035 creator A5018946153 @default.
• W2969884035 creator A5021929797 @default.
• W2969884035 creator A5029294865 @default.
• W2969884035 creator A5042248757 @default.
• W2969884035 creator A5053161165 @default.
• W2969884035 creator A5056910106 @default.
• W2969884035 creator A5080355474 @default.
• W2969884035 creator A5086486271 @default.
• W2969884035 creator A5089208862 @default.
• W2969884035 date "2019-11-01" @default.
• W2969884035 modified "2023-10-11" @default.
• W2969884035 title "Treatment of the antiphospholipid syndrome with direct oral anticoagulants" @default.
• W2969884035 cites W2054330426 @default.
• W2969884035 cites W2417628371 @default.
• W2969884035 cites W2791992225 @default.
• W2969884035 cites W2792756092 @default.
• W2969884035 cites W2803799996 @default.
• W2969884035 cites W2813643485 @default.
• W2969884035 cites W2836138182 @default.
• W2969884035 cites W2886953225 @default.
• W2969884035 cites W2892827065 @default.
• W2969884035 cites W2913486724 @default.
• W2969884035 cites W4376542722 @default.
• W2969884035 doi "https://doi.org/10.1024/0301-1526/a000815" @default.
• W2969884035 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31621546" @default.
• W2969884035 hasPublicationYear "2019" @default.
• W2969884035 type Work @default.
• W2969884035 sameAs 2969884035 @default.
• W2969884035 citedByCount "16" @default.
• W2969884035 countsByYear W29698840352020 @default.
• W2969884035 countsByYear W29698840352021 @default.
• W2969884035 countsByYear W29698840352022 @default.
• W2969884035 countsByYear W29698840352023 @default.
• W2969884035 crossrefType "journal-article" @default.
• W2969884035 hasAuthorship W2969884035A5000085570 @default.
• W2969884035 hasAuthorship W2969884035A5018946153 @default.
• W2969884035 hasAuthorship W2969884035A5021929797 @default.
• W2969884035 hasAuthorship W2969884035A5029294865 @default.
• W2969884035 hasAuthorship W2969884035A5042248757 @default.
• W2969884035 hasAuthorship W2969884035A5053161165 @default.
• W2969884035 hasAuthorship W2969884035A5056910106 @default.
• W2969884035 hasAuthorship W2969884035A5080355474 @default.
• W2969884035 hasAuthorship W2969884035A5086486271 @default.
• W2969884035 hasAuthorship W2969884035A5089208862 @default.
• W2969884035 hasConcept C126322002 @default.
• W2969884035 hasConcept C2776301958 @default.
• W2969884035 hasConcept C2776874634 @default.
• W2969884035 hasConcept C2778205648 @default.
• W2969884035 hasConcept C2778661090 @default.
• W2969884035 hasConcept C2779161974 @default.
• W2969884035 hasConcept C2780022809 @default.
• W2969884035 hasConcept C2780842393 @default.
• W2969884035 hasConcept C2780868729 @default.
• W2969884035 hasConcept C71924100 @default.
• W2969884035 hasConcept C90924648 @default.
• W2969884035 hasConceptScore W2969884035C126322002 @default.
• W2969884035 hasConceptScore W2969884035C2776301958 @default.
• W2969884035 hasConceptScore W2969884035C2776874634 @default.
• W2969884035 hasConceptScore W2969884035C2778205648 @default.
• W2969884035 hasConceptScore W2969884035C2778661090 @default.
• W2969884035 hasConceptScore W2969884035C2779161974 @default.
• W2969884035 hasConceptScore W2969884035C2780022809 @default.
• W2969884035 hasConceptScore W2969884035C2780842393 @default.
• W2969884035 hasConceptScore W2969884035C2780868729 @default.
• W2969884035 hasConceptScore W2969884035C71924100 @default.
• W2969884035 hasConceptScore W2969884035C90924648 @default.
• W2969884035 hasIssue "6" @default.
• W2969884035 hasLocation W29698840351 @default.
• W2969884035 hasLocation W29698840352 @default.
• W2969884035 hasOpenAccess W2969884035 @default.
• W2969884035 hasPrimaryLocation W29698840351 @default.
• W2969884035 hasRelatedWork W2097468114 @default.
• W2969884035 hasRelatedWork W2161939736 @default.
• W2969884035 hasRelatedWork W2339926357 @default.
• W2969884035 hasRelatedWork W2376859318 @default.
• W2969884035 hasRelatedWork W2414445665 @default.
• W2969884035 hasRelatedWork W2437082741 @default.
• W2969884035 hasRelatedWork W2499714385 @default.
• W2969884035 hasRelatedWork W2910563879 @default.
• W2969884035 hasRelatedWork W3013727226 @default.
• W2969884035 hasRelatedWork W3127172482 @default.
• W2969884035 hasVolume "48" @default.
• W2969884035 isParatext "false" @default.
• W2969884035 isRetracted "false" @default.
• W2969884035 magId "2969884035" @default.
• W2969884035 workType "article" @default.